CJC-1295 Whitout DAC

Buy CJC-1295 No DAC: High-Purity Mod GRF 1-29 Research Peptide

Are you looking to buy CJC-1295 no DAC from a manufacturer that verifies purity on every batch? Sino Research Peptide Manufacturer supplies CJC-1295 (no DAC), also known as Modified GRF 1-29 or Mod GRF (1-29) — a synthetic peptide analog built from the first 29 amino acids of natural GH-releasing hormone (GHRH, also called GRF in research literature).

What Is CJC-1295 (No DAC)?

This peptide includes specific amino acid substitutions that improve stability and reduce enzymatic breakdown. These modifications also increase binding to GHRH receptors in laboratory models while helping the peptide resist DPP-IV cleavage and oxidation.

Sino Research Peptide Manufacturer supplies CJC-1295 (no DAC) as a high-purity lyophilized powder, typically reaching 99% purity or higher through HPLC testing. It’s commonly available in 2 mg or 5 mg research vials. Researchers use this compound to study pulsatile GH secretion, pituitary signaling, and IGF-1 axis activity. The peptide is intended strictly for in vitro and in vivo laboratory research and isn’t approved for human consumption or therapeutic use.

Buy CJC-1295 No DAC Mechanism of Action

In preclinical studies, Buy CJC-1295 no DAC acts as a selective GHRH receptor agonist. It binds to receptors on pituitary somatotroph cells, activating Gs-protein signaling pathways. This interaction increases intracellular cAMP levels and activates protein kinase A, triggering pulsatile release of endogenous GH.

The peptide has a short half-life of approximately 30 minutes, producing brief, controlled GH pulses that closely resemble natural hypothalamic and pituitary regulation. Unlike DAC variants, it doesn’t cause prolonged GH elevation. Laboratory studies demonstrate increased GH pulse amplitude and IGF-1 upregulation without receptor desensitization during short exposure periods.

Buy CJC-1295 No DAC Peptide Sequence

CJC-1295 (no DAC) is a linear peptide composed of 29 amino acids with C-terminal amidation for enhanced stability.

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

Key Substitutions

• D-Ala at position 2 — resists DPP-IV cleavage
• Gln at position 8 — reduces deamidation
• Ala at position 15 — improves bioactivity
• Leu at position 27 — prevents oxidation

Chemical Specifications

These molecular modifications improve peptide stability and support consistent receptor interaction throughout laboratory experiments.

Buy CJC-1295 No DAC 2mg and 5mg: Which Size Fits Your Study?

CJC-1295 (no DAC) comes in standard research vial sizes to match different study needs.

2mg Vial

The 2 mg vial suits small-scale experiments, including cell culture assays and early dose testing, giving your lab precise concentration control after reconstitution.

5mg Vial

The 5 mg vial supports larger or repeated studies, including long-term animal models, GH pulse analysis, and IGF-1 kinetics research. Larger quantities also improve cost efficiency for extended research work.

Both formats arrive as white lyophilized powder and require reconstitution using sterile or bacteriostatic water under controlled laboratory conditions.

CJC-1295 (No DAC) Research Findings

Researchers widely use CJC-1295 (no DAC) in preclinical research involving cell-based assays and rodent models focused on pulsatile GH secretion. Studies demonstrate dose-dependent increases in GH release alongside elevated IGF-1 levels, all while maintaining natural GH pulsatility.

The peptide supports investigation of endocrine signaling, receptor interaction, and metabolic pathways, including lipolysis and protein synthesis. Research models often examine muscle repair mechanisms and adipose tissue metabolism.

Compared with DAC variants, the no-DAC form allows improved control over hormone pulse timing, making it particularly valuable for studying natural GH rhythms. The compound remains investigational and lacks regulatory approval for human use.

How to Store and Handle CJC-1295 (No DAC)

Proper storage protects peptide integrity throughout your research timeline.

• Store unopened vials in a cool, dark, dry environment.
• For long-term storage, keep vials at −20°C; sealed vials may remain stable at 2–8°C for several months.
• Protect the peptide from light exposure and moisture, and avoid temperature fluctuations during storage.
• After reconstitution, refrigerate the solution at 2–8°C and use within four to six weeks.
• Avoid repeated freeze-thaw cycles, and always follow sterile laboratory handling procedures with proper PPE.

Where to Buy CJC-1295 Without DAC

CJC-1295 No DAC For Sale at Sino Research Peptide Manufacturer

When you’re comparing where to buy CJC-1295, purity documentation and consistent synthesis should top your checklist. Sino Research Peptide Manufacturer verifies identity and purity on every batch, giving your lab confidence in the material behind your data.

Purchase CJC-1295 No DAC Online

Whether your lab needs the 2 mg or 5 mg format, Sino Research Peptide Manufacturer makes it simple to buy CJC-1295 no DAC online, backed by rigorous internal quality checks on every batch.

Best Place to Buy CJC-1295 Without DAC

Look for a supplier that documents HPLC purity results, states clear research-use terms, and ships consistent, batch-verified material — Sino Research Peptide Manufacturer builds each of these standards into every order.

Order CJC-1295 (No DAC) Today

Ready to add CJC-1295 (no DAC) to your research pipeline? Sino Research Peptide Manufacturer makes ordering straightforward, with documented quality on every vial.

Disclaimer: CJC-1295 (no DAC) is an investigational research peptide intended solely for in vitro laboratory research and in vivo animal studies. It is not approved by the FDA, EMA, or any regulatory authority for human use, diagnosis, treatment, or supplementation. The compound is classified as a non-approved substance and is prohibited in athletic contexts. Preclinical findings do not predict human outcomes, and no claims are made regarding safety or efficacy in humans. Products should be handled only in qualified research facilities under institutional oversight and are strictly sold for laboratory research use only.

References:

1. National Center for Biotechnology Information. “PubChem Compound Summary for CID 91976842, CJC1295 Without DAC” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC
2. Clark, R G, and I C Robinson. “Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats.” Nature vol. 314,6008 (1985): 281-3. https://pubmed.ncbi.nlm.nih.gov/2858818/
3. The Discovery of Growth Hormone-Releasing Hormone: An Update https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2826.2008.01740.x
4. Martin, B., Lopez de Maturana, R., Brenneman, R., Walent, T., Mattson, M. P., & Maudsley, S. (2005). Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular medicine, 7(1-2), 3–36. https://doi.org/10.1385/nmm:7:1-2:003
5. Newton, A. C., Bootman, M. D., & Scott, J. D. (2016). Second Messengers. Cold Spring Harbor perspectives in biology, 8(8), a005926. https://doi.org/10.1101/cshperspect.a005926
6. Khorram, O., Laughlin, G. A., & Yen, S. S. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism, 82(5), 1472–1479. https://doi.org/10.1210/jcem.82.5.3943
7. Ito T, Igarashi H, Pradhan TK, Hou W, Mantey SA, Taylor JE, Murphy WA, Coy DH, Jensen RT. GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity. Peptides. 2001 Jul;22(7):1139-51. https://pubmed.ncbi.nlm.nih.gov/11445245/
8. Schally AV, Zhang X, Cai R, Hare JM, Granata R, Bartoli M. Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists. Endocrinology. 2019 Jul 1;160(7):1600-1612. https://pubmed.ncbi.nlm.nih.gov/31070727/
9. Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30